Joseph Eron, MD
Infectious Disease · Chapel Hill, NCNPI 1598838336
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $159,781 of the $195,382 with a category attached, or 81.8%. 7 manufacturers reported payments, led by Merck at 44.5% of the total. Among infectious disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $1085.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$87K
- Viiv Healthcare Company$54K
- Gilead$40K
- GSK$5K
- Janssen Scientific Affairs, LLC$4K
- Shionogi Inc$3K
- plus $2K from 1 others
Across 322 payments — averaging $2812.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$560K
- Viiv Healthcare Company$245K
- Janssen Research & Development, LLC$101K
What the payments were for
- Royalty or licence$2620%
- Consulting fees$159,78182%
- Speaking & faculty fees$3,1822%
- Grants$4,2272%
- Travel & lodging$24,92013%
- Food & beverage$3,0022%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 84 | $86,870 |
| Viiv Healthcare Company | 46 | $54,404 |
| Gilead | 40 | $39,755 |
| GSK | 3 | $5,025 |
| Janssen Scientific Affairs, LLC | 4 | $4,489 |
| Shionogi Inc | 2 | $3,189 |
| AbbVie | 1 | $1,650 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$195,382 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 144 | $593,699 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 62 | $266,437 |
| TivicayDolutegravir Sodium | 98 | $261,940 |
| DescovyEmtricitabine/Tenofov Alafenam | 108 | $239,282 |
| PifeltroDoravirine | 62 | $106,890 |
| RukobiaFostemsavir Tromethamine | 12 | $103,138 |
| CabenuvaCabotegravir/Rilpivirine | 14 | $88,504 |
| PrezcobixDarunavir/Cobicistat | 35 | $87,269 |
| DovatoDolutegravir Sodium/Lamivudine | 25 | $71,881 |
| JulucaDolutegravir/Rilpivirine | 19 | $66,264 |
| IsentressRaltegravir Potassium | 17 | $34,259 |
| Maraviroc | 13 | $13,911 |
| OzempicSemaglutide | 11 | $10,484 |
| NorvirRitonavir | 14 | $3,510 |
| Ritonavir | 14 | $2,595 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $39,755 | $832,981252 claims |
| Viiv Healthcare CompanyTivicay, Rukobia, Cabenuva, Dovato, Juluca | $54,404 | $591,727168 claims |
| MerckPifeltro, Isentress | $86,870 | $141,14979 claims |
| AbbVieNorvir | $1,650 | $3,51014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.
Other infectious disease in Chapel Hill
- David WohlChapel Hill$726K
- David van DuinChapel Hill$67K
- Adaora AdimoraChapel Hill$52K
- Myron CohenChapel Hill$40K
- David MargolisChapel Hill$36K
- Michelle Floris MooreChapel Hill$23K
- Arlene SoberanoChapel Hill$19K
- Sarah RutsteinChapel Hill$8K
- Lisa Hightow-WeidmanChapel Hill$3K
- Anna Rosengren-HoveeChapel Hill$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.